$527.07
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
United Therapeutics Insider Sold Shares Worth $5,056,298, According to a Recent SEC Filing
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
Overview
52-week range
$272
$609
76% of range
Avg surprise (last 3)
-4.6%
Avg reaction (last 2)
+2.5%
100% positive
Latest IV / EM
38%
EM ±8.7% · $530 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $5.82 | $6.73 | -13.5% | -12.2% | +4.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $7.16 | — | — | — | — | financials |
| Wed Jul 30, 2025 | Jun/2025 | $6.41 | $6.80 | -5.7% | — | — | earnings |
| Wed Apr 30, 2025 | Mar/2025 | $6.63 | $6.29 | +5.4% | — | +0.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $6.39 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $5.85 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $6.17 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $5.38 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $5.24 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Jul 29, 2026 | Jun/2026 | OTHER | $6.83 | $6.41 | +6.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $133M | — | $101M | $88M | $92M | — | $83M | $78M |
| Gross profit | $648M | — | $699M | $711M | $702M | — | $666M | $637M |
| Operating income | $326M | — | $388M | $364M | $383M | — | $343M | $320M |
| Net income | $275M | — | $339M | $310M | $322M | — | $309M | $278M |
| EPS (diluted) | $5.82 | — | $7.16 | $6.41 | $6.63 | — | $6.39 | $5.85 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.28B | $1.56B | $1.34B | $1.59B | $1.90B | $1.70B | $1.55B | $1.36B |
| Inventory | $178M | $183M | $176M | $169M | $165M | $158M | $147M | $136M |
| Total current assets | $2.87B | $3.70B | $3.49B | $3.83B | $3.94B | $3.87B | $4.00B | $3.62B |
| Total assets | $6.71B | $7.88B | $7.35B | $7.91B | $7.74B | $7.36B | $7.12B | $6.72B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $813M | $784M | $761M | $734M | $937M | $920M | $1.02B | $1.03B |
| Total equity | $5.90B | $7.10B | $6.59B | $7.17B | $6.81B | $6.44B | $6.10B | $5.70B |